Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
G Toyokawa, T Seto, M Takenoyama… - Cancer and Metastasis …, 2015 - Springer
Anaplastic lymphoma kinase (ALK) has been identified to exert a potent transforming activity
through its rearrangement in non-small cell lung cancer (NSCLC), and patients (pts) with …
through its rearrangement in non-small cell lung cancer (NSCLC), and patients (pts) with …
[HTML][HTML] Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: a review of the literature
Brain metastasis (BM) is the most common event in patients with lung cancer. Despite
multimodal treatments and advances in systemic therapies, development of BM remains one …
multimodal treatments and advances in systemic therapies, development of BM remains one …
Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung …
PL Su, YL Wu, WY Chang, CL Ho… - Therapeutic …, 2018 - journals.sagepub.com
Introduction: Brain metastases (BM) are common in advanced non-small cell lung cancer
(NSCLC), and the prognosis is poor with few therapeutic options. This study evaluated the …
(NSCLC), and the prognosis is poor with few therapeutic options. This study evaluated the …
[HTML][HTML] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
K Dong, W Liang, S Zhao, M Guo, Q He… - Translational Lung …, 2019 - ncbi.nlm.nih.gov
Background It has been confirmed that epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) presented better efficacy than brain radiotherapy (brain RT) in the …
inhibitors (EGFR-TKIs) presented better efficacy than brain radiotherapy (brain RT) in the …
[HTML][HTML] Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer
MY Baek, HK Ahn, KR Park, HS Park… - The Korean Journal …, 2018 - ncbi.nlm.nih.gov
Methods We retrospectively investigated the medical records of 259 patients diagnosed with
advanced NSCLC from January 2010 to August 2013, who were tested for EGFR mutations …
advanced NSCLC from January 2010 to August 2013, who were tested for EGFR mutations …
Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations
Objective Patients with lung adenocarcinoma (ADC) are at higher risk of the development of
brain metastasis (BM), and genetic alterations are associated with BM. Patients and …
brain metastasis (BM), and genetic alterations are associated with BM. Patients and …
[HTML][HTML] Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases
Background To determine the clinical benefits of systemic targeted agents across multiple
histologies after stereotactic radiosurgery (SRS) for brain metastases. Methods Between …
histologies after stereotactic radiosurgery (SRS) for brain metastases. Methods Between …
[HTML][HTML] Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant …
Q Zhu, Y Sun, Y Cui, K Ye, C Yang, D Yang, J Ma… - Oncotarget, 2017 - ncbi.nlm.nih.gov
This study compared treatment outcomes between TKI monotherapy and TKI administration
combined with brain radiotherapy (TKI+ RT) in 133 non-small cell lung cancer (NSCLC) …
combined with brain radiotherapy (TKI+ RT) in 133 non-small cell lung cancer (NSCLC) …
Lung cancer in women, a different disease: survival differences by sex in Turkey
Purpose: In this study, we aimed to evaluate the effects of sex-based non-small cell lung
cancer (NSCLC) varieties on survival rates. Materials and Methods: A retrospective study …
cancer (NSCLC) varieties on survival rates. Materials and Methods: A retrospective study …
[HTML][HTML] Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma
X Ma, H Zhu, H Guo, A Han, H Wang, W Jing, Y Zhang… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Controversial value of prophylactic cranial irradiation (PCI) in NSCLC in terms of survival
benefit prompted us to explore the possible risk factors for brain metastasis (BM) during the …
benefit prompted us to explore the possible risk factors for brain metastasis (BM) during the …